Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX)
{{output}}
Introduction: This Phase I study evaluated the safety and tolerability of concurrent niraparib, an oral poly(ADP-ribose) polymerase (PARP) 1/2 inhibitor, with definitive radiotherapy in women with locally advanced or platinum-sen... ...
